VC investment and exit activity in the biopharma sector rose in Q3. Exit value hit $9.7 billion—up from $5 billion in Q2—headlined by Merck’s $3 billion acquisition of EyeBio, an eye disease specialist backed by Bain Capital and Samsara BioCapital. Generative AI has driven considerable excitement for applications like protein engineering, PitchBook’s latest Emerging Tech Research shows. Radiopharmaceuticals, which use radioactive isotopes to design targeted drugs, is another innovation hot spot.
Read the full article: Biopharma Exits Nearly Double with $3B Boost from EyeBio Sale //
Source: https://pitchbook.com/news/reports/q3-2024-biopharma-report